Michael Fraser to receive NACDS Foundation Excellence in Patient Care award
The National Association of Chain Drug Stores Foundation will honor Michael Fraser, CEO of the Association of State and Territorial Health Officials, or ASTHO, for his distinguished leadership in addressing the opioid-abuse epidemic and in advancing maternal and children’s health, as well as other healthcare priorities.
Fraser will accept the award at the 20th Annual NACDS Foundation Dinner on Nov. 28, 2018 at the Sheraton New York Times Square in New York City.
ASTHO is the national nonprofit organization representing the public health agencies of the United States, the U.S. territories and freely associated states, and Washington, D.C.
Fraser has advanced ASTHO’s mission as an advocate, voice and resource for state and territorial public health since August 2016. He is currently a collaborating editor and author of “A Public Health Guide to Ending the Opioid Crisis,” slated to be published by Oxford University Press in early 2019.
Fraser has served as an educator, innovator and distinguished leader in public health. Prior to joining ASTHO, he served as executive vice president and CEO of the Pennsylvania Medical Society, as CEO of the Association of Maternal and Child Health Programs, and as deputy executive director of the National Association of County and City Health Officials. He also has served in several capacities at the U.S. Department of Health and Human Services.
“We look forward to recognizing the tremendous leadership of Dr. Fraser and the entire ASTHO team,” NACDS Foundation president Kathleen Jaeger said. “At ASTHO and throughout his career, Dr. Fraser has provided unique leadership to help prevent opioid abuse and to advance maternal and children’s health — both of which stand among the priorities of the NACDS Foundation.”
McKesson announces Hammergen’s retirement, chooses successors
McKesson has announced the retirement of its chairman and CEO John Hammergen, effective March 31, 2019. The company’s board has unanimously elected Brian Tyler, who currently is president and COO of the San Francisco-based company, to succeed him as CEO, effective April 1, 2019. Edward Mueller, McKesson’s lead independent director, will become chairman, also effective April 1, 2019.
“It has been an honor to serve as McKesson’s CEO for nearly 20 years,” Hammergren said. “We are making solid progress with our strategic growth initiative and the company is in a strong financial position. This is the right time to turn the leadership reins over to the next generation and no one is better equipped than Brian to lead McKesson into the future. He is a gifted leader with deep industry knowledge and an unwavering commitment to enhancing value for our customers and their patients.”
Since Hammergen became CEO in April 2001, McKesson said that it has quadrupled its revenues to $208 billion, expanded into global markets and reached the No. 6 spot on the Fortune 500. He also has established the company’s ICARE shared principles, which the company said underpin its value and culture globally.
Hammergen’s planned successor, Tyler, has been with McKesson for 21 years, leading nearly every major business unit, as well as its corporate strategy and business development unit. He has served as CEO of McKesson Europe, led the company’s North American pharmaceutical distribution services, overseen McKesson U.S. Pharmaceutical, McKesson Medical-Surgical and McKesson Specialty Care Solutions. He joined the company in 1997 as vice president of strategy for the McKesson’s distribution solutions unit.
“Brian is the ideal leader to guide McKesson through the next era,” said Mueller. “Having spent his entire career in healthcare, he has a strong point of view on the future of the industry, both in the U.S. and globally, as well as how McKesson will continue to play an integral role in improving care while driving value for McKesson’s shareholders.”
Mueller, who will become chairman, has been a McKesson director since 2008, serving as lead independent director since July 2013. His career experience has included a stint as chairman and CEO of Qwest Communications, CEO of Williams Sonoma and CEO of Ameritech.
“Ed Mueller will be a terrific chairman of our Board of Directors,” said Hammergren. “During his 10 years of service on our Board, Ed has developed a deep knowledge of McKesson and our industry. He has the respect of our board, McKesson’s leaders and our investors.”
McKesson said its board would work with Hammergen, Tyler and Mueller to ensure a smooth transition. Following his retirement, Hammergen will remain chairman of the Change Healthcare board, and will support McKesson in an advisory capacity, the company said.
Study: Misuse of acetaminophen combo products in decline
A recent study published in the journal Clinical Toxicology found a decline in the incidence of therapeutic misuse of OTC combination products with acetaminophen during the 10 years between 2007 and 2016. The new study follows a 2016 Food and Drug Administration study in Pharmacoepidemiology and Drug Safety.
The study, funded by the Consumer Health Products Association, used data from the National Poison Data System to identify when consumers exceeded the maximum dose of an ingredient while using it for its intended purpose for products containing acetaminophen. Overall, the number of therapeutic misuse involving OTC combination products with acetaminophen dropped from 8,753 in 2007 to 6,278 in 2016 — a decline of 28%.
“When used as labeled and directed, acetaminophen is safe and effective,” said Barbara Kochanowski, senior vice president of regulatory and scientific affairs at CHPA. “This research provides reassuring evidence that incidents of misuse are rare and continue decreasing. But consumer education is key to continuing this downward trend.”
The study’s authors noted that continued consumer education is necessary to highlight the safe use of acetaminophen. The CHPA Educational Foundation helps lead the Acetaminophen Awareness Coalition, which launched the “Know Your Dose” campaign, that looks to educate consumers about safe use of the medication to prevent accidental overdoses, in 2011.
“We remain committed to efforts aimed at reducing these incidents,” Kochanowski said. “In addition to our consumer education campaign, the OTC industry, in collaboration with FDA, provides clear packaging, labeling, dosing, directions, appropriate warnings and education to help physicians and consumers who rely on these medicines.”